2,645 Shares in Revvity Inc. $RVTY Acquired by Callan Family Office LLC

Callan Family Office LLC acquired a new position in Revvity Inc. (NYSE:RVTY) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 2,645 shares of the company’s stock, valued at approximately $256,000.

Several other large investors have also bought and sold shares of the company. Wealth Enhancement Advisory Services LLC lifted its position in shares of Revvity by 3.8% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 5,139 shares of the company’s stock valued at $544,000 after acquiring an additional 187 shares in the last quarter. Ritholtz Wealth Management acquired a new position in shares of Revvity in the 1st quarter valued at about $210,000. Amalgamated Bank lifted its position in shares of Revvity by 1.0% in the first quarter. Amalgamated Bank now owns 23,777 shares of the company’s stock worth $2,516,000 after purchasing an additional 227 shares in the last quarter. Family Legacy Financial Solutions LLC acquired a new stake in shares of Revvity during the second quarter worth approximately $5,351,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Revvity by 11.1% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,415 shares of the company’s stock valued at $1,417,000 after purchasing an additional 1,343 shares in the last quarter. Institutional investors own 86.65% of the company’s stock.

Revvity Stock Up 2.0%

Revvity stock opened at $94.00 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.33 and a quick ratio of 2.75. Revvity Inc. has a fifty-two week low of $81.36 and a fifty-two week high of $129.50. The firm has a fifty day moving average price of $88.46 and a two-hundred day moving average price of $92.53. The firm has a market cap of $10.91 billion, a price-to-earnings ratio of 39.83, a P/E/G ratio of 3.07 and a beta of 0.98.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Monday, July 28th. The company reported $1.18 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.04. The company had revenue of $720.28 million during the quarter, compared to analyst estimates of $711.26 million. Revvity had a return on equity of 7.66% and a net margin of 10.19%.The company’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same period in the previous year, the company earned $1.22 earnings per share. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS. As a group, analysts forecast that Revvity Inc. will post 4.94 earnings per share for the current year.

Revvity Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 7th. Shareholders of record on Friday, October 17th will be issued a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, October 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.3%. Revvity’s dividend payout ratio (DPR) is presently 11.86%.

Wall Street Analyst Weigh In

RVTY has been the topic of a number of research reports. Raymond James Financial reaffirmed an “outperform” rating and issued a $115.00 price target (down from $120.00) on shares of Revvity in a research note on Tuesday, July 29th. Stifel Nicolaus dropped their target price on Revvity from $120.00 to $110.00 and set a “hold” rating on the stock in a research report on Tuesday, July 29th. Bank of America reduced their price target on Revvity from $110.00 to $99.00 and set a “buy” rating for the company in a report on Monday, September 22nd. Evercore ISI lowered their price target on Revvity from $108.00 to $106.00 and set an “outperform” rating for the company in a research note on Tuesday, October 7th. Finally, Barclays dropped their price objective on Revvity from $110.00 to $100.00 and set an “overweight” rating on the stock in a report on Thursday, October 2nd. Nine equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $116.62.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.